113 related articles for article (PubMed ID: 18722111)
1. Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007.
Wilcken N; Dear R
Eur J Cancer; 2008 Oct; 44(15):2218-25. PubMed ID: 18722111
[TBL] [Abstract][Full Text] [Related]
2. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
Jiang J; Liang X; Zhou X; Huang R; Chu Z
Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
[TBL] [Abstract][Full Text] [Related]
3. The use of chemotherapy in metastatic breast cancer.
Garber JE; Henderson IC
Hematol Oncol Clin North Am; 1989 Dec; 3(4):807-21. PubMed ID: 2481671
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin in combination therapy for metastatic breast cancer.
Perez EA
Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
[TBL] [Abstract][Full Text] [Related]
6. Combination versus sequential single-agent therapy in metastatic breast cancer.
Miles D; von Minckwitz G; Seidman AD
Oncologist; 2002; 7 Suppl 6():13-9. PubMed ID: 12454315
[TBL] [Abstract][Full Text] [Related]
7. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
National Institutes of Health Consensus Development Panel
J Natl Cancer Inst Monogr; 2001; (30):5-15. PubMed ID: 11773285
[TBL] [Abstract][Full Text] [Related]
8. Single-agent docetaxel (Taxotere) in randomized phase III trials.
Burris HA
Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
[TBL] [Abstract][Full Text] [Related]
9. [Palliative chemotherapy for metastatic breast cancer with capecitabine].
Inaba T; Kashiwaba M; Takeda Y; Komatsu H; Tomisawa Y; Takiyama I; Wakabayashi G
Gan To Kagaku Ryoho; 2009 May; 36(5):769-72. PubMed ID: 19461175
[TBL] [Abstract][Full Text] [Related]
10. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib for the treatment of HER2-overexpressing breast cancer.
Jones J; Takeda A; Picot J; von Keyserlingk C; Clegg A
Health Technol Assess; 2009 Oct; 13 Suppl 3():1-6. PubMed ID: 19846022
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of taxane-containing regimens for metastatic breast cancer.
Ghersi D; Wilcken N; Simes RJ
Br J Cancer; 2005 Aug; 93(3):293-301. PubMed ID: 16052223
[TBL] [Abstract][Full Text] [Related]
14. Emerging drugs in metastatic breast cancer: an update.
Arslan C; Altundag K; Dizdar O
Expert Opin Emerg Drugs; 2011 Dec; 16(4):647-67. PubMed ID: 22122529
[TBL] [Abstract][Full Text] [Related]
15. Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicentre OMEGA study.
Hamaker ME; Seynaeve C; Nortier JW; Wymenga M; Maartense E; Boven E; van Leeuwen-Stok AE; de Rooij SE; van Munster BC; Smorenburg CH
Breast; 2013 Aug; 22(4):556-9. PubMed ID: 23305962
[TBL] [Abstract][Full Text] [Related]
16. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity.
Hryniuk W; Frei E; Wright FA
J Clin Oncol; 1998 Sep; 16(9):3137-47. PubMed ID: 9738586
[TBL] [Abstract][Full Text] [Related]
17. [Cancer chemotherapy based on evidence--metastatic breast cancer].
Takashima S; Saeki T; Ohsumi S
Gan To Kagaku Ryoho; 2000 Jan; 27(1):44-51. PubMed ID: 10660732
[TBL] [Abstract][Full Text] [Related]
18. Highlights in metastatic breast cancer from the 2012 American Society of Clinical Oncology Annual Meeting.
Perez EA
Clin Adv Hematol Oncol; 2012 Sep; 10(9 Suppl 14):1-24. PubMed ID: 23072923
[No Abstract] [Full Text] [Related]
19. Counterpoint: the argument for combination chemotherapy in the treatment of metastatic breast cancer.
Cianfrocca M; Gradishar WJ
J Natl Compr Canc Netw; 2007 Sep; 5(8):673-5. PubMed ID: 17927925
[TBL] [Abstract][Full Text] [Related]
20. [Taxanes in metastatic breast cancer. An analysis of a systematic Cochrane review].
Nielsen DL; Kamby C
Ugeskr Laeger; 2006 Sep; 168(37):3117-20. PubMed ID: 16999914
[No Abstract] [Full Text] [Related]
[Next] [New Search]
